MIRA
INFORM REPORT
|
Report Date : |
04.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
RESEARCH PHARMACEUTICAL LTD. |
|
|
|
|
Registered Office : |
Rm. C, 21/F, Qianjiang Building, No. 971, Dongfang Road, Pudong New District, Shanghai, 200122 Pr |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
10.03.2005 |
|
|
|
|
Com. Reg. No.: |
310115500100172 |
|
|
|
|
Legal Form : |
Representative Office |
|
|
|
|
Line of Business : |
Subject is engaged in business liaison of importing and
exporting pharmaceutical raw materials, pesticide and plant extracts |
|
|
|
|
No. of Employees : |
05 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
RESEARCH
PHARMACEUTICAL LTD. SHANGHAI OFFICE
RM. C, 21/F, QIANJIANG BUILDING, NO. 971,
DONGFANG ROAD,
PUDONG NEW DISTRICT, SHANGHAI, 200122 PR CHINA
TEL: 86 (0) 21-68406232 FAX:
86 (0) 21-68406233
EXECUTIVE SUMMARY
INCORPORATION DATE : MAR. 10, 2005
REGISTRATION NO. : 310115500100172
REGISTERED LEGAL FORM : REPRESENTATIVE OFFICE
CHIEF EXECUTIVE : MS. LI MEIFEN (PRINCIPAL)
STAFF STRENGTH : 5
REGISTERED CAPITAL : N/A
BUSINESS LINE : LIAISON
TURNOVER :
N/A
EQUITIES :
N/A
PAYMENT :
NOT YET DETERMINED
RECOMM. CREDIT RANGE :
SMALL AMOUNT
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION :
N/A
OPERATIONAL TREND :
FAIRLY STEADY
GENERAL REPUTATION :
AVERAGE
EXCHANGE RATE :
CNY 6.36 = USD 1
Adopted
abbreviations:
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
Note: SC’s correct address should be the heading one, while the given address (Oriental Intl. Science Bldg., Floor 16-1, No. 58 Shanghai) was SC’s former address; SC’s complete name should be the heading one.
SC was registered as a
representative office at local Administration for Industry & Commerce
(AIC - The official body of issuing and renewing business license) on Mar. 10,
2005.
Company Status:
Representative office Foreign company, which has
entered into a contract with a PR China co., is permitted to establish a
representative office in PR China. The representative office may engage
only in “non-direct operating activities” such as liaison, consulting,
market research & general information gathering. At present,
representative office is not allowed to employ local employees in its own
name and must use PR China employment agencies.
SC’s registered business scope includes engaged in
non-profit business activities related to foreign parent company
SC is
mainly engaged in business liaison of importing and exporting pharmaceutical raw
materials, pesticide and plant extracts.
Ms. Li
Meifen has been principal of SC since 2005.
SC is known to have approx. 5 employees at
present.
SC
is currently operating at the above stated address, and this address houses its
operating office in the commercial zone of Shanghai. Our checks reveal that SC
rents the total premise about 127 square meters.
SC is not known to host website of its own at present.
Changes of its registered information:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registration
no. |
14612 |
Present one |
Parent company:
Research
Pharmaceutical Ltd. (Hong Kong)
Research
Pharmaceutical Limited is a comprehensive company which focuses on medical-related
businesses both home and abroad.
Web: http://www.researchpharmaceutical.com/
*Company Registration*
===================
(1)
License number : 712318
Date issued : 12 April,
2000
Issuing authority : Companies
Registry
Type of license : Corporate
(2)
License number : 30881351
Date issued : N/A
Issuing authority : Business
Registration Office - Inland Revenue Dept
Type of license :
Business
*Capital Details*
=============
Authorized capital: HKD 10,000.00 divided into 10,000 ordinary shares of
HKD 1.00/-each, fully paid
*Major Shareholders*(as of Jul., 2007)
===========================
Total number of shareholders
: 2
Total number of ordinary shares : 10,000
Shareholders' Name No. of Ordinary
Shares Amount of Shares
(HKD) % of Shares
-------------------------- ------------------------------- --------------------------------- ----------------
WES CO INC
9,500
9,500.00
95.00
DIOPHRAM SA
500
500.00
5.00
*Director's Details*
===============
(1)
Jairo Alfonso Escobar Ramirez
Passport no. : CC 16627602
Address :
Zona Franca de Bogota - Bodega 6, 15-25
(2)
Cesar Orrego Echeverry
Passport no. :
CC-16764635
Address :
Zona Franca de Bogota - Bodega 6, 15-25
(3)
Susana Helena Ortega Peterson
Passport no. :
CC31281137
Address :
Zona Franca de Bogota - Bodega 6, 15-25
*Corporate Secretary*
=================
OVERSEAS COMSEC LTD
CR no. : 655275
Address : 2706 Times Square - Tower One 1 Matheson St, Cause Bay, Hong
Kong
Principal:
Ms. Li Meifen , in her
Working
Experience(s):
From 2005 to present Working in SC as principal
SC is
mainly engaged in business liaison of importing and exporting pharmaceutical
raw materials, pesticide and plant extracts.
SC’s products mainly include: pharmaceutical raw materials,
pesticides and plant extracts.
SC
is not known to have any subsidiary at present.
Overall payment appraisal:
( ) Excellent (
) Good ( ) Average
( ) Fair (
) Poor (X) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
Industrial & Commercial Bank of China Shanghai Lujiazui
Sub-branch
AC#N/A
Relationship:
Normal
As a representative office, SC is not allowed
to engage in direct business. All its expenses are supposed to be provided by
its parent company. Therefore, its financial information is not available.
SC is a representative office, which is not engaged in
direct business.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.81 |
|
UK Pound |
1 |
Rs.86.04 |
|
Euro |
1 |
Rs.69.62 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.